Sign in

CIK 0001796280 · Non-accelerated filer

Oric Pharmaceuticals, Inc.

Sign in to watch
Ticker
ORIC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
471787157
Phone
(650) 388-5600
Business address
240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$1,519,090
in 5 filings, $1.5M under 10b5-1 plans

Net −$1,519,090. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2020-04-28 GORDON CARL L Director Conversion · Series D Preferred Stock −236,111 0
2020-04-28 Chacko Jacob President and CEO Conversion +62,500 62,500
2020-04-28 Chacko Jacob President and CEO Conversion · Series C Preferred Stock −62,500 0
2020-04-24 ORBIMED ADVISORS LLC Director Purchase +281,250 $16.00 $4.5M 281,250
2020-04-24 GORDON CARL L Director Purchase +281,250 $16.00 $4.5M 281,250
2020-04-23 Multani Pratik S Chief Medical Officer Grant or award · Stock Option (right to buy) +147,500 147,500
2020-04-23 Piscitelli Dominic Chief Financial Officer Grant or award · Stock Option (right to buy) +86,250 86,250
2020-04-23 Dier Mardi Director Grant or award · Stock Option (right to buy) +33,250 33,250
2020-04-23 Svennilson Peter Director Grant or award · Stock Option (right to buy) +16,625 16,625
2020-04-23 SCHELLER RICHARD H Director Grant or award · Stock Option (right to buy) +33,250 33,250
2020-04-23 Heyman Richard A. Director Grant or award · Stock Option (right to buy) +16,625 16,625
2020-04-23 GORDON CARL L Director Grant or award · Stock Option (right to buy) +16,625 16,625
2020-04-23 Chacko Jacob President and CEO Grant or award · Stock Option (right to buy) +437,500 437,500

Page 18 of 18 · 353 trades